Nation-wide use of guideline-directed medical therapies in heart failure across the ejection fraction range: The HECMOS study

13 May 2024 (12:25 - 13:34)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Ioannis Leontsinis

Hippokration General Hospital, Athens (Greece)

4 More presentations in this session

Presentation thumbnail

What factors are associated with myocardial recovery following admission for acute heart failure? Study in patients with de novo diagnosis and reduced left ventricular ejection fraction

Mr V. Donoso (Valencia, ES)

Abstract Slides Video

Presentation thumbnail

SGLT2i treatment at the beginning of real time exposure in a HFrEF population

Associate Professor V. Vintila (Bucharest, RO)

Abstract Slides Video

Presentation thumbnail

The daily challenges to patients posed by diuretic therapy; what they are and what do patients do?

Doctor G. Bruno (Limerick, IE)

Abstract Slides Video

Presentation thumbnail

CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and cardiorenal syndrome

Mr G. Nunez Marin (Valencia, ES)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in chronic heart failure - pharmacotherapy 6

The Event

Event poster

Heart Failure 2024

13 May 2024 12:25 CET

You may be interested in

Congress Presentation

Guideline directed medical treatment and comorbidity burden among patients admitted with acute HF decompensation: insights from the HECMOS 2.0

Congress Presentation

Real-life management of heart failure: evaluation of medication optimisation in different phenotypes.

Congress Presentation

Initiation and titration of prognostic drug therapy during hospitalization for acute decompensation of heart failure with reduced ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources